21 A novel mechanism of action was described, when a protease-activated receptor 4 (P4Pal 10 ) 22 derived lipopeptide (pepducin) was shown to inhibit signaling downstream of several unrelated 23 Gq-coupled receptors. We show that this putative Gq-inhibiting pepducin lacks inhibitory 24 effects on signaling downstream of the Gαq-coupled receptors for ATP (P2Y 2 R) and PAF 25 (PAFR) expressed in human neutrophils. P4Pal 10 inhibited however, signaling in neutrophils 26 activated with agonists for the Gi-coupled formyl peptide receptor 2 (FPR2) but not the 27 closely related FPR1. In addition, the P4Pal 10 pepducin was turned into an activating agonist in 28 the presence of an allosteric modulator selective for free fatty acid receptor 2 (FFA2R). The 29 results presented thus reveal Gq-independent effects of P4Pal 10 in modulating FPR2-and 30 FFA2R-mediated neutrophil activation. 31 32 Number of words: 120 33 Key words: G-protein coupled receptors (GPCRs), formyl peptide receptors (FPRs), NADPH-34 oxidase, pepducins, protease-activated receptor 4 (PAR4), neutrophils. 35 36 37 3 39 Introduction 40 41 Receptors belonging to the G-protein-coupled receptor (GPCR) family constitute a class of 42 recognition molecules involved in a broad range of physiological processes as well as 43 pathological conditions (1). The GPCRs have in common that they are polypeptides that span 44 a cell membrane seven times, and the transmembrane-spanning α-helices connect the N-45 terminal tail and three loops expressed on the cell surface, with three intracellular loops and a 46 C-terminal tail facing the cytosolic compartment (2). To mediate a cellular response following 47 recognition of an extracellular ligand that binds to its membrane exposed binding 48 cavity/domain, the cytosolic domains are structurally and functionally modified to allow and 49 mediate an intracellular coupling to a so-called heterotrimeric G-protein containing an α-and a 50 β/γ subunit (3). There are four classes of α-subunits, designated as Gαs, Gαq, Gαi/o and 51 Gα12/13, which initiate distinct as well as overlapping signaling cascades (3). The Gα subunit 52 part possesses an intrinsic GTPase activity which keeps signaling of a receptor at a very low or 53 zero level in the absence of an agonist (4). The conformational changes in the receptor, initiated 54 by the binding of an agonist, promotes an exchange of GDP for GTP, which leads to 55 dissociation and activation of the Gα subunit and a start of the G-protein dependent signaling 56 cascade (3). The large structural similarities between G-proteins makes it hard to determine the 57 precise identity of a signaling partner, and two bacterial toxins (pertussis toxin from Bordetella 58 pertussis and cholera toxin from Vibro cholera) have for long been the only tools available to 59 investigate receptor coupling to Gαi (sensitive to pertussis toxin) and Gαs (sensitive to cholera 60 toxin), respectively (5, 6). New and more efficient inhibitors of specific G-protein subunits have 61 been eagerly awaited and small molecule inhibitors of Gαq are now available (7, 8). These 62 inhibitors (the depsipeptide YM-254890 and the analog FR900359) selectively target Gαq 63 signaling through an inhibition of the GDP/GTP exchange, and signaling is thus selectively 64 terminated downstream of the Gαq-protein.
158 PAFR and P2Y 2 R, is not inhibited by the P4Pal 10 pepducin 159 One of the very early events in neutrophils following activation by G-protein coupled receptor 160 (GPCR) selective agonists, is the induction of the PLC-PIP 2 -IP 3 intracellular signaling pathway 161 leading to an increase in the intracellular/cytosolic concentration of free Ca 2+ ([Ca 2+ ] i ) (19). The 162 Gq-coupled GPCRs for the lipid chemoattractant platelet activating factor (PAFRs) and for 163 ATP (P2Y 2 Rs) are abundantly expressed by neutrophils. In accordance with the general 164 signaling scheme, stimulation of these GPCRs with their respective receptor specific agonist 10 214 The P4Pal 10 pepducin abolished WKYMVM-induced O 2production, and the inhibition was 215 P4Pal 10 concentration dependent with an IC 50 -value of ~ 0.7 µM ( Fig 3A) . To further investigate 216 whether the inhibitory effect of P4Pal 10 is restricted to the agonist WKYMVM or achieved on 217 the level of FPR2, we used several other FPR2 selective agonists including the Staphylococcus 218 aureus-derived PSM2 peptide (28), the mitochondrial-derived MCT-ND4 peptide (29), the 219 lipidated peptidomimetic agonist Compound 14 (13), and the activating FPR2 specific pepducin 220 F2Pal 10 (12, 30). All these FPR2 agonists activate neutrophils and P4Pal 10 inhibited the 221 response ( Fig 3B) . These data clearly show that the P4Pal 10 pepducin inhibits FPR2-mediated 222 neutrophil activation, and the inhibition is at the level of receptor rather than on the specific 223 ligand used.
224 The P4Pal 10 pepducin blocked FPR2-mediated activation also in monocytes but lacked effect 225 on binding of WKYMVM to FPR2 226 In addition to neutrophils that abundantly express FPR1 and FPR2, also monocytes express the 227 two members of the FPRs in addition to the third family member FPR3 (23). To determine 228 whether the P4Pal 10 pepducin selectively targets FPR2-but not FPR1-signaling also in 229 monocytes, we purified human blood-derived monocytes using CD14 negative selection 230 magnetic beads and the monocyte purity was confirmed using CD14 antibody (Fig 4 A) . Very 231 similar to the results obtained from neutrophils, the P4Pal 10 pepducin preferentially inhibited 232 also the FPR2 but not FPR1-mediated O 2production when monocytes were used ( Fig 4B, C) .
233 Despite the clear inhibitory effect of the P4Pal 10 pepducin on FPR2-mediated responses in both 234 neutrophils and monocytes, our experiments in which P4Pal 10 competes with a Cy5-labeled 235 WKYMVM in binding to cell membrane exposed FPR2, show that the pepducin does not affect 236 agonist binding ( Fig 4D) . Binding of Cy5-WKYMVM to FPR2 was, however, inhibited by 237 non-labeled WKYMVM in large excess ( Figure 4D ). 238 240 neutrophil NADPH oxidase 241 In addition to FPR2, neutrophils express also pattern recognition FFA2R that sense short free 242 fatty acids (22) . In contrast to the FPR2 agonists used above, the FFA2R agonist propionate 243 cannot alone trigger an activation of the NADPH-oxidase, but the allosteric FFA2R modulator 244 Cmp58 turns propionate into a potent activator of the NADPH-oxidase (27, 31). Our results not 245 only confirmed the effect of Cmp58 on propionate but also revealed that this allosteric 246 modulator turned also the P4Pal 10 pepducin into a potent neutrophil activator ( Fig 5A) . In the 247 presence of Cmp58, the P4Pal 10 -induced O 2release was of the same magnitude as that induced 248 by propionate ( Fig 5A inset) . The P4Pal 10 -induced response was inhibited by an FFA2R 249 antagonist ( Fig 5A) , clearly showing that the response is mediated through FFA2R. To further 250 characterize the P4Pal 10 -induced activation of the neutrophil NADPH-oxidase, we determined 251 the priming effect of TNFα on this response. In agreement with our previous data with 252 propionate as the activating agonist (20), the P4Pal 10 response in the presence of Cmp58 was 253 greatly augmented in TNFα primed cells ( Fig 5B) . In addition, we found that the primed P4Pal 10 254 response was sensitive to the Gq inhibitor YM-254890 ( Fig 5B and Fig 5C) . The amount of 255 O 2production was not significant altered when the order of the Cmp58 and P4Pal 10 was 256 reversed upon stimulation (inset Fig 5D) but the onset of the response was somewhat delayed 257 ( Fig 5D) . Taken together, these data clearly demonstrate that together with an allosteric FFA2R 258 modulator, P4Pal 10 acts as a potent FFA2R agonist that activates the neutrophil NADPH 259 oxidase. 276 GPCR pepducins were introduced some 15 years ago as allosteric receptor modulators with a 277 unique mechanism of action directly involving the cytosolic signaling parts of the receptor (9).
278 According to the suggested model, the peptide part of a pepducin determines the receptor 279 specificity that is fine-tuned by the identity at the level of the amino acid sequence in the peptide 280 part of pepducin and one of cytosolic receptor domains (9), and with an absolute fit between 281 these, the pepducin either activates or inhibits receptor function. The P4Pal 10 pepducin operates, 282 however, not only on the cognate receptor (PAR4) from which it was derived, but also on 283 receptors that do not share a strong sequence homology with the pepducin (11). The background 284 to the receptor promiscuity of the inhibition mediated by the P4Pal 10 pepducin was suggested 285 to be linked to the recruitment of the signaling G-protein down-stream of the targeted receptors, 286 with the common denominator being that the sensitive receptors signal through a Gαq 13 288 not apply to human neutrophils as P4Pal 10 inhibited signaling transduced by the Gαi-coupled 289 FPR2 but not by the Gαq-coupled receptors investigated. In addition, we expanded the P4Pal 10 -290 targeting GPCRs by including also FFA2R, a receptor designed to recognize short chain fatty 291 acids. The molecular background to the effects of P4Pal 10 on FPR2 and FFA2R cannot be fitted 292 into the original pepducin concept stating that the peptide sequence of a receptor modulating 293 pepducin, should be present also in one of the cytosolic parts of the targeted receptor. There are 294 no sequence similarities between P4Pal 10 (peptide sequence (SGRRYGHALR)) and any of the 295 cytosolic parts of FPR2 and FFA2R. The basis for our study was that P4Pal 10 was claimed to 296 be an inhibitor of Gq signaling, with an inhibition profile across multiple receptor subtypes, 297 of which some have no or very limited sequence similarity in their intracellular domains, with 298 the third intracellular loop of PAR4 from which the amino acid sequence in the P4Pal 10 299 pepducin was derived (32). The precise mechanism by which P4Pal 10 affects the diverse set of 300 G q -coupled receptors (11), thus, remains elusive, but according to the pepducin concept, 301 P4Pal 10 should affect some unknown but critical intra-receptor or receptor-G protein interaction 302 site that is necessary for the down-stream signaling promoted selectively by a Gq protein. It 303 is clear from the data presented, that the putative Gαq inhibitory pepducin P4Pal 10 does not 304 inhibit the Gαq-coupled neutrophil receptors PAFR and P2Y 2 R in human neutrophils, 305 suggesting that the unknown critical interaction site required for inhibition is missing in these 306 receptors.
307 More importantly, we present some novel modes of action of P4Pal 10 ; it antagonizes the Gαi-308 coupled FPR2 and activates the allosterically modulated FFA2Rs. It should also be noticed, that 309 the effect of Cmp58 on the P2Pal 10 induced response was the same as when the order of addition 310 was reversed and the pepducin was used as sensitizing ligand. This type of allosteric interaction 311 is reciprocal in nature and the results presented are, thus, in agreement with the reciprocity 312 characterizing receptor allosterism. As mentioned, the pepducin dogma states that active 313 pepducins are expected to allosterically modulate receptor function through an interaction with 314 an intracellular receptor-specific binding site; the fatty acid anchors the pepducin to the cell 315 membrane and allow the peptide part to flip over and enter the cytosol to interact and activate 316 or inhibit signaling by its cognate receptor (9). We have in a series of earlier studies presented 317 data that strongly challenge the dogma when showing that, i) even though and FPR2 derived 318 pepducin is a highly selective activating FPR2 agonist, its activity is inhibited by conventional 319 orthosteric antagonists, ii) there is no direct link between the amino acid sequence in the 320 targeted receptor and in the activating/inhibiting pepducin and, iii) pepducins with peptide 321 sequences derived from intracellular domains present in several GPCRs hijack FPR2 (33-35).
322 Irrespective of the precise mode of action of P4Pal 10 , we now add the putative Gq inhibitor 323 P4Pal 10 to the list of FPR2 hijacking pepducins, and this together with earlier published data 324 raise questions not only about the general mode of action of pepducins but also about FPR2 and 325 FFA2R as pattern recognition receptors for some type of endogenous or microbe-derived, lipid-326 substituted peptides that might represent an additional molecular pattern that is recognized by 327 and activate or inhibit FPRs/FFARs. 328 In summary, we show that the putative Gαq inhibitory pepducin P4Pal 10 does not inhibit the 329 Gαq-coupled PAFR and P2Y 2 R expressed in in neutrophils but the lipopeptide selectively 330 antagonizes the Gαi-coupled FPR2. In addition, we show that an allosteric FFA2R modulator 331 turns P4Pal 10 into an activator of the O 2generating neutrophil NADPH oxidase. 
